Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Interest Expenses (2016 - 2025)

Ligand Pharmaceuticals' Interest Expenses history spans 16 years, with the latest figure at $1.8 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 101.24% year-over-year to $1.8 million; the TTM value through Dec 2025 reached $4.7 million, up 55.25%, while the annual FY2025 figure was $4.7 million, 55.25% up from the prior year.
  • Interest Expenses for Q4 2025 was $1.8 million at Ligand Pharmaceuticals, up from $910000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $5.8 million in Q1 2021 and bottomed at $1000.0 in Q3 2023.
  • The 5-year median for Interest Expenses is $828000.0 (2022), against an average of $1.5 million.
  • The largest annual shift saw Interest Expenses crashed 99.7% in 2023 before it surged 74000.0% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $4.5 million in 2021, then crashed by 94.62% to $240000.0 in 2022, then plummeted by 45.42% to $131000.0 in 2023, then soared by 577.1% to $887000.0 in 2024, then soared by 101.24% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Interest Expenses are $1.8 million (Q4 2025), $910000.0 (Q3 2025), and $1.2 million (Q2 2025).